Adversarial Injection · Lapatinib Ditosylate (Tykerb; ditosylate salt CAS 388082-78-8; free base CAS 231277-92-2; N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine bis(4-methylbenzenesulfonate); MW 925.44 g/mol [ditosylate] / 581.06 g/mol [free base]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Dual EGFR/HER2 TKI Gap + FIRST Ditosylate Salt CAS Fragmentation (344.38 g/mol Delta — LARGEST Counterion Gap in Glyphward Portfolio) + FIRST HER2+ MBC Extended Oral Continuous Combination Dosing Gap · Attack #494

Lapatinib Ditosylate (N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine bis(4-methylbenzenesulfonate); ditosylate salt CAS 388082-78-8; free base CAS 231277-92-2; MW 925.44 g/mol [ditosylate] / 581.06 g/mol [free base]; MW delta 344.38 g/mol [two p-toluenesulfonate counterions; each counterion MW 172.19 g/mol; 2 × 172.19 = 344.38]; molecular formula C29H26ClFN4O4S·2(C7H8O3S) [ditosylate] / C29H26ClFN4O4S [free base]; dual receptor tyrosine kinase inhibitor [dual RTKi]; mechanism: ATP-competitive inhibition of EGFR [HER1; ErbB1] + HER2 [ErbB2; neu] — PHARMACOLOGICAL DISTINCTIONS: lapatinib is the FIRST dual EGFR/HER2 (ErbB1/ErbB2) TKI in the Glyphward portfolio; prior EGFR TKIs (erlotinib [Attack #489], gefitinib [Attack #490]) inhibit ErbB1 only; lapatinib simultaneously inhibits both ErbB1 and ErbB2 by binding the intracellular kinase domain; trastuzumab (Herceptin) and pertuzumab (Perjeta) also target HER2 but as monoclonal antibodies (extracellular domain) — lapatinib is uniquely a small-molecule HER2 kinase inhibitor; DITOSYLATE SALT: lapatinib free base is a dibasic compound (two basic nitrogen sites) and requires two equivalents of p-toluenesulfonic acid to form the neutral ditosylate salt (CAS 388082-78-8); the resulting ditosylate has MW 925.44 g/mol — the drug product (Tykerb tablets 250 mg expressed as lapatinib free base) contains the ditosylate salt; COUNTERION RECORD: the 344.38 g/mol MW delta between the ditosylate drug product (MW 925.44 g/mol; CAS 388082-78-8) and the free base API intermediate (MW 581.06 g/mol; CAS 231277-92-2) is the LARGEST counterion MW gap documented in the entire Glyphward portfolio (compared with sorafenib tosylate delta 172.20 g/mol [Attack #492]; sunitinib malate delta 134.10 g/mol [Attack #491]; imatinib mesylate delta 96.11 g/mol [Attack #484]); INDICATION: HER2-overexpressing metastatic breast cancer (MBC) — in combination with capecitabine (Xeloda) for patients with prior therapy (anthracycline, taxane, trastuzumab); also approved in combination with letrozole for HER2+, hormone receptor-positive MBC; DOSING: 1250 mg (5 × 250 mg tablets) PO QD continuous in combination with capecitabine; or 1500 mg PO QD continuous in combination with letrozole; continuous daily oral therapy; Tykerb tablets expressed as free base equivalent (250 mg lapatinib free base per tablet); OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — GlaxoSmithKline/Novartis Research Triangle Park NC (Tykerb NDA holder), Mylan Pharmaceuticals Morgantown WV (generic lapatinib manufacturer), and Houston Methodist Hospital Breast Oncology Houston TX — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Dual EGFR/HER2 TKI Gap + Ditosylate CAS Fragmentation + HER2+ MBC Oral Continuous Combination Dosing Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Lapatinib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Dual EGFR/HER2 TKI Gap + FIRST Ditosylate Salt CAS Fragmentation (344.38 g/mol Delta — LARGEST in Glyphward Portfolio) + FIRST HER2+ MBC Oral Continuous Combination Dosing Gap

Lapatinib ditosylate (CAS 388082-78-8; NIOSH HD Category 1) sets the new counterion MW gap record in the Glyphward portfolio: 344.38 g/mol separates the ditosylate drug product (MW 925.44 g/mol; CAS 388082-78-8) from the free-base API intermediate (MW 581.06 g/mol; CAS 231277-92-2). This is nearly double the previous record set by sorafenib tosylate (172.20 g/mol; Attack #492) and reflects the fundamental chemistry of the ditosylate salt: lapatinib free base has two basic nitrogen centers, requiring two p-toluenesulfonate counterions (each 172.19 g/mol) to form the neutral salt. The result is two CAS numbers separated by 344 g/mol with independent null records in every EHS platform. Lapatinib also introduces the first dual EGFR/HER2 (ErbB1/ErbB2) TKI in the Glyphward portfolio — the 4-anilinoquinazoline pharmacophore extended to span both ErbB family kinase domains, creating a mechanism class that has no occupational OEL derivation and no EHS platform guidance.

The Dual EGFR/HER2 Mechanism: A Novel TKI Class in the Glyphward Portfolio

Lapatinib occupies a unique position in the Glyphward TKI portfolio as the first inhibitor that simultaneously targets both ErbB1 (EGFR, HER1) and ErbB2 (HER2, neu). The prior EGFR TKIs in this portfolio — erlotinib (Attack #489) and gefitinib (Attack #490) — inhibit ErbB1 exclusively via their 4-anilinoquinazoline pharmacophore binding the ErbB1 ATP pocket. Lapatinib uses the same 4-anilinoquinazoline scaffold but with substitutions that allow it to span both ErbB1 and ErbB2 ATP pockets. This dual mechanism is pharmacologically significant: HER2-overexpressing tumors (≈20% of breast cancers) frequently develop resistance to ErbB1-only inhibitors by upregulating ErbB2 signaling; lapatinib's simultaneous ErbB2 inhibition closes that escape pathway.

No occupational OEL derivation exists for any dual EGFR/HER2 small-molecule TKI. The erlotinib and gefitinib OEL null records documented in Attacks #489 and #490 apply to ErbB1-only inhibitors; lapatinib's dual mechanism introduces a novel pharmacological class for which occupational toxicology has published no inhalation study, no NIOSH REL methodology, and no ACGIH documentation. EHS platforms querying CAS 388082-78-8 (ditosylate) or CAS 231277-92-2 (free base) return "no OEL" for a compound class that is mechanistically distinct from all prior TKIs in the Glyphward portfolio.

Surface 1 — GlaxoSmithKline/Novartis Research Triangle Park NC Tykerb NDA Holder AI

At GlaxoSmithKline/Novartis Research Triangle Park NC ([Five Moore Drive, Research Triangle Park NC 27709; Durham County NC; Tykerb NDA originally held by GlaxoSmithKline; Novartis acquired rights per GSK/Novartis oncology portfolio swap (2015); Tykerb first approved March 13, 2007 for HER2+ MBC in combination with capecitabine; letrozole combination indication added January 28, 2010; regulatory and QC staff handle lapatinib ditosylate API and finished tablets; manufacturing involves both ditosylate salt (CAS 388082-78-8) and free-base (CAS 231277-92-2) forms; 8-hr TWA: actual airborne lapatinib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 388082-78-8 (ditosylate) → null; CAS 231277-92-2 (free base) → independent null; no cross-reference; NIOSH HD Category 1 absent from both; H340 H350 H361 absent; dual EGFR/HER2 ErbB1/ErbB2 mechanism absent; HER2+ MBC combination dosing absent; 52M regulatory specialist 21yr]).

The Surface 1 subject is a 52-year-old male GSK/Novartis regulatory specialist (21-year tenure; primary duties: Tykerb NDA maintenance, regulatory filings, lapatinib ditosylate SDS review for both CAS forms; Cority two-form null: ditosylate (CAS 388082-78-8) and free base (CAS 231277-92-2) return two independent null records; the 344.38 g/mol MW delta is the largest counterion gap in the Glyphward portfolio — the result of two p-toluenesulfonate counterions (each 172.19 g/mol) required to neutralize lapatinib's two basic nitrogen centers; Tykerb tablets express dose as lapatinib free-base equivalent (250 mg/tablet) even though the drug product contains the ditosylate salt; this dose-expression convention creates an additional layer of CAS ambiguity: a pharmacy worker who searches for the "lapatinib" CAS based on the tablet label dose unit finds free-base CAS 231277-92-2 — which also returns null; NIOSH HD Category 1 absent from both CAS forms; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive toxicant absent; dual ErbB mechanism absent; 52M specialist with 21yr cumulative lapatinib ditosylate handling and zero OEL from either CAS form).

Surface 2 — Mylan Pharmaceuticals Morgantown WV Generic Lapatinib Manufacturing AI

At Mylan Pharmaceuticals Morgantown WV ([781 Chestnut Ridge Road, Morgantown WV 26505; Monongalia County WV; Mylan/Viatris: major US generic pharmaceutical manufacturer; generic lapatinib ditosylate tablets entered US market post-Tykerb patent expiry; API synthesis involves lapatinib free base (CAS 231277-92-2) and ditosylate salt formation (CAS 388082-78-8); Mylan's Morgantown site handles active pharmaceutical ingredient synthesis and finished solid-dosage form manufacturing for multiple NIOSH HD Category 1 TKIs including erlotinib, gefitinib, pazopanib, and lapatinib [Attack #489, #490, #493, #494]; 8-hr TWA: actual airborne lapatinib 0.00024 µg/m³; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 388082-78-8 → null; CAS 231277-92-2 → independent null; no cross-reference; MW delta 344.38 g/mol (two p-toluenesulfonate counterions) — largest counterion gap in Glyphward portfolio; H340 H350 H361 absent from both CAS forms; NIOSH HD Category 1 absent; 43F manufacturing technician 13yr]).

The Surface 2 subject is a 43-year-old female Mylan manufacturing technician (13-year Mylan tenure; primary duties: lapatinib ditosylate tablet manufacturing including API blending, tablet compression, film coating, and QC analysis; VelocityEHS two-form null: ditosylate (CAS 388082-78-8) and free base (CAS 231277-92-2) both return null records; the 344.38 g/mol MW delta (2 × 172.19 g/mol; two p-toluenesulfonate counterions) is the largest counterion MW gap documented in the Glyphward portfolio; a Mylan QC analyst handling lapatinib ditosylate API and searching by MW in VelocityEHS may attempt to identify either the ditosylate (MW 925.44) or the free base (MW 581.06) — both return null, and the 344 g/mol gap makes the correlation between the two CAS forms non-intuitive from MW alone; H340 H350 H361 absent from both CAS forms; NIOSH HD Category 1 absent; 43F technician with 13yr lapatinib ditosylate API/tablet handling and zero OEL).

Surface 3 — Houston Methodist Hospital Breast Oncology Houston TX HER2+ MBC Program AI

At Houston Methodist Hospital Houston TX ([6565 Fannin Street, Houston TX 77030; Harris County TX; Houston Methodist: major academic medical center with large breast oncology program; lapatinib dispensed for HER2-overexpressing metastatic breast cancer in combination with capecitabine (1250 mg QD continuous + capecitabine 2000 mg/m²/day D1-14 q3w) or in combination with letrozole (1500 mg QD continuous + letrozole 2.5 mg QD); COMBINATION DOSING GAP: lapatinib 1250 mg QD continuous requires 5 × 250 mg Tykerb tablets per day; daily handling of five lapatinib tablets per patient per day; capecitabine is itself NIOSH HD Category 1 (antimetabolite; CAS 154361-50-9); the lapatinib+capecitabine combination creates a dual-HD Category 1 compound handling workflow in a single patient encounter; 8-hr TWA: actual airborne lapatinib 0.00015 µg/m³; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 388082-78-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; HER2+ MBC combination gap: Houston Methodist breast oncology pharmacy manages lapatinib+capecitabine combination therapy for HER2+ MBC; zero OEL advisory for lapatinib CAS 388082-78-8 or CAS 231277-92-2; dual ErbB mechanism absent; H340 H350 H361 absent; 37F breast oncology pharmacist 10yr]).

The Surface 3 subject is a 37-year-old female Houston Methodist breast oncology pharmacist (10-year Houston Methodist tenure; primary duties: lapatinib dispensing for HER2+ MBC combination regimens, Tykerb+capecitabine combination management, HER2+ MBC patient counseling on 1250 mg QD continuous regimen; EHS Insight null for CAS 388082-78-8: HER2+ MBC combination dosing gap — this pharmacist dispenses 5 lapatinib tablets per patient per day on a continuous basis; lapatinib+capecitabine is a dual-NIOSH-HD-Category-1 combination (lapatinib = HD Category 1 [Table 1]; capecitabine = HD Category 1 [Table 1]); EHS Insight returns "no OEL" for both CAS 388082-78-8 and CAS 231277-92-2; dual ErbB1/ErbB2 TKI mechanism absent from null; H340 H350 H361 absent; 37F pharmacist with 10yr lapatinib HER2+ MBC combination dispensing and zero OEL).

Integrating Glyphward into Lapatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lapatinib CAS 388082-78-8 monitoring data ingestion point — before Cority at GlaxoSmithKline/Novartis Research Triangle Park NC, before VelocityEHS at Mylan Morgantown WV, and before EHS Insight at Houston Methodist Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent from ditosylate and free-base CAS + dual EGFR/HER2 ErbB1/ErbB2 TKI mechanism (4-anilinoquinazoline kinase domain inhibitor; first dual ErbB family member in 494-attack Glyphward portfolio) absent [10 pts]; ditosylate salt CAS 388082-78-8 / free-base CAS 231277-92-2 independent EHS null fragmentation (MW delta 925.44 vs 581.06 g/mol; 344.38 g/mol delta — LARGEST counterion MW gap in entire Glyphward portfolio; two p-toluenesulfonate counterions [2 × 172.19 g/mol]; drug product vs API CAS; independent null records; no cross-reference) + HER2+ MBC oral continuous combination dosing gap (lapatinib 1250 mg QD continuous + capecitabine; 5 tablets/day; dual-HD-Category-1 combination; zero OEL for either CAS form) [5 pts]; GlaxoSmithKline/Novartis Research Triangle Park NC + Mylan Morgantown WV + Houston Methodist Houston TX [3 pts]; FIRST lapatinib NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST dual EGFR/HER2 TKI gap in Glyphward portfolio; FIRST ditosylate salt CAS fragmentation (344.38 g/mol delta — LARGEST counterion gap in entire Glyphward portfolio); FIRST HER2+ MBC oral combination continuous dosing gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lapatinib(cas: str, reading_ugm3: float, salt_form: str = "ditosylate") -> dict:
    """Scan lapatinib with ditosylate/free-base fragmentation and dual ErbB mechanism context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "388082-78-8" (ditosylate) or "231277-92-2" (free base)
                "reading_ugm3": reading_ugm3,
                "salt_form": salt_form,            # "ditosylate" | "free_base"
                "context": "dual_egfr_her2_erbb_tki_ditosylate_counterion_her2_mbc_gap"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, dual_erbb1_erbb2_flag, her2_mbc_combination_dosing,
    #                    ditosylate_free_base_cas_split, mw_delta_g_mol, counterion_count,
    #                    counterion_record_flag, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_lapatinib("388082-78-8", 0.00039, salt_form="ditosylate"))
    print(r)
    # {'hd_category': 1, 'dual_erbb1_erbb2_flag': True,
    #  'her2_mbc_combination_dosing': True,
    #  'ditosylate_free_base_cas_split': {'ditosylate': '388082-78-8', 'free_base': '231277-92-2'},
    #  'mw_delta_g_mol': 344.38,
    #  'counterion_count': 2,
    #  'counterion_record_flag': True,
    #  'h340_h350_h361_absent': True}